NIH has released R01 and R21 versions of this funding opportunity. Its objective is to encourage research aimed at clarifying the cellular and molecular mechanisms underlying the presence and function of eosinophil leukocytes in eosinophilic associated rare diseases such as, but not limited to, Eosinophilic Gastrointestinal Disorders (EGIDs), Hypereosinophilic Syndrome (HES) and Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome.
Eosinophil-associated disorders are a group of uncommon medical conditions in which the eosinophil is considered to have a primary or an important pathophysiologic role. Such disorders can affect the skin, upper and lower airways, cardiovascular system, connective tissues, gastrointestinal tract, the hematopoietic and immune systems, and other organs. However, despite the abundance of these cells, the pathophysiologic roles that eosinophils play in these disorders are not well understood. As a result, treatment options are limited and are associated with significant untoward problems. From a patient’s perspective, not only the limited treatment options, but also physicians’ limited knowledge of eosinophil-associated diseases can be detrimental to physical and psychological health and can result in substantial quality-of-life restrictions. This can also affect the emotional and social lives of the patients’ families.
Specific areas of research interest:
- Research on the fundamental immuno-biologic and mechanistic roles of human eosinophils in Eosinophil-Associated Disorders.
- Development of predictive biomarkers and clinical outcomes for Eosinophil-Associated Disorders
- Development of novel therapeutic targets for use in Eosinophil-Associated Disorders
- Preclinical evaluation of existing therapeutic agents for use in Eosinophil-Associated Disorders
- Identification and improvement of novel invasive and non-invasive techniques for the diagnosis and clinical monitoring of Eosinophil-Associated Disorders
- Improvement of diagnostic criteria that delineate differential phenotypes within Eosinophil-Associated Disorders
- Development of novel animal models with improved predictive value for human Eosinophilic-Associated Disorders
Deadlines: standard NIH deadlines apply
R01 version, http://grants.nih.gov/grants/guide/pa-files/PA-15-027.html
R21 version: http://grants.nih.gov/grants/guide/pa-files/PA-15-028.html
Filed Under: Funding Opportunities